BlinkLab Ltd
ASX:BB1
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.26
1.085
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BlinkLab Ltd
An app that turns an ordinary mobile phone into a device for conducting objective neurobehavioral tests could make it easier and more cost-effective to diagnose neurological disorders. The company is headquartered in Sydney, New South Wales. The company went IPO on 2024-04-04. The Company’s tests include eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response, which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The BlinkLab Device (BlinkLab Dx) consists of BlinkLab App, a mobile application for patients, caregivers and/or parents, effectively a front-end tool that helps collect test subjects’ information and responses to the BlinkLab Tests in real time (BlinkLab App), and BlinkLab Portal, which includes a fully built secure database and content management system (CMS) as well as experimenter’s portal that allows for full customization of the neurometric tests as well as data analysis, annotation and visualization tools (the BlinkLab Portal).
An app that turns an ordinary mobile phone into a device for conducting objective neurobehavioral tests could make it easier and more cost-effective to diagnose neurological disorders. The company is headquartered in Sydney, New South Wales. The company went IPO on 2024-04-04. The Company’s tests include eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response, which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The BlinkLab Device (BlinkLab Dx) consists of BlinkLab App, a mobile application for patients, caregivers and/or parents, effectively a front-end tool that helps collect test subjects’ information and responses to the BlinkLab Tests in real time (BlinkLab App), and BlinkLab Portal, which includes a fully built secure database and content management system (CMS) as well as experimenter’s portal that allows for full customization of the neurometric tests as well as data analysis, annotation and visualization tools (the BlinkLab Portal).
